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Abstract Purpose: Reliable mea-
sures are required for proper cost–
utility analysis after critical care. No
gold standard is available, but the
EQ-5D health-related quality of life
instrument (HRQoL) has been pro-
posed. Our aim was to compare the
EQ-5D with another utility measure,
the 15D, after critical illness. Meth-
ods: A total of 929 patients ﬁlled in
both the EQ-5D and 15D HRQoL
instruments 6 and 12 months after
treatment at an intensive care or high-
dependency unit. The difference in
the medians and distributions of the
scores of the instruments was tested
with Wilcoxon signed-rank test and
their association with Spearman rank
correlation. Discriminatory power
was compared by the ceiling effect
and agreement between the
instruments regarding the direction of
the minimal clinically important
change in the HRQoL scores between
6 and 12 months was tested with the
McNemar-Bowker test and Cohen’s
kappa. Results: The utility scores
produced by the instruments and their
distributions were different. Agree-
ment between the instruments was
only moderate. The 15D appeared
more sensitive than the EQ-5D both
in terms of discriminatory power and
responsiveness to clinically important
change. Conclusion: The agreement
between the two utility measures was
only moderate. The choice of the
instrument may have a substantial
effect on cost-utility results. Our
results suggest that the 15D performs
well after critical illness, but further
large cohort studies comparing dif-
ferent utility instruments in this
patient population are warranted
before the gold standard for utility
measurement can be announced.
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Introduction
Health-related quality of life (HRQoL) is an important
patient-reported outcome after critical illness. In the
intensive care context, several generic proﬁle instruments,
such as the SF-36 [1], the Sickness Impact Proﬁle [2], and
the Nottingham Health Proﬁle [3], have been used. Also,
the EQ-5D, a generic utility instrument enabling the
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allowing the comparison of the cost-utility of interven-
tions across different medical specialities, has been used
[4–8]. Although no HRQoL instrument can claim to be
the gold standard, the 2002 Brussels Roundtable Con-
sensus meeting recommended the SF-36 and EQ-5D as
the preferred HRQoL instruments in the critical care
setting [9], but at the same time encouraged further
methodological research and instrument design.
There is still an evident lack of comparisons between
utility instruments in the critical care setting. The RAND-
36 (SF-36) and the EQ-5D have been compared, and the
former turned out to have slightly more discriminatory
power [10]. However, the EQ-5D is currently the most
widely used utility instrument worldwide for the calcu-
lation of QALYs [11]. Thus, it seemed appropriate to
choose it in this study as the comparator to the 15D,
which is the most frequently used utility instrument in
Finland, although a possibility to generate a utility score
(SF-6D) also from the SF-36 data has been introduced
[12]. The 15D and EQ-5D have previously been com-
pared in a number of other populations and patient groups
[13–15], but not in critical care.
Materials and methods
Patients
The data were collected prospectively in the Helsinki
University Hospital between 1 January 2003 and 31
December 2004. The study was approved by the local
Ethics Committee. Informed consent was obtained from
the patients. The study population consisted of 3,600
patients treated in two intensive care (ICU) and three
high-dependency units (HDU).
HRQoL instruments
The EQ-5D and 15D were mailed to patients alive and
with a known address 6 and 12 months after admission to
the ICU or HDU together with an accompanying letter
and an informed consent form. The patients were asked to
return the questionnaires and the consent in a prepaid
envelope. In case of non-response, one reminder was sent.
Possible readmissions after the index admission did not
start a new follow-up.
The EQ-5D consists of ﬁve dimensions: mobility, self-
care, usual activities, pain or discomfort, and anxiety or
depression. Each dimension is divided into three levels:
no problems, some problems and severe problems.
Instead of the Finnish VAS-based valuation algorithm
used in some earlier Finnish critical care studies [5, 16],
we used the UK time-trade-off (TTO) ‘‘tariff,’’ which is
the most commonly used valuation system for the EQ-5D.
According to it the utility scores range from -0.59 to 1,
where 1 means full health and 0 stands for death. No
health state can obtain a score between 0.88 and 0.99, and
negative scores indicate health states worse than death
[17]. The minimal clinically important difference (MID)
for the EQ-5D TTO is about 0.08 [18].
The 15D consists of 15 dimensions: breathing, mental
function, speech, vision, mobility, usual activity, vitality,
hearing, eating, elimination, sleeping, distress, discomfort
and symptoms, depression and sexual activity. Each
dimension is divided into ﬁve levels from no problems to
extremeproblems.Theutilityscoresofthe15Drangefrom
0 to 1, with 1 being equivalent to full health and 0 to death
[19]. The MID of the 15D has been estimated as 0.03 [20].
Statistical analysis
The mean and median scores of the two instruments at
6 months were calculated. The visual inspection of the
distribution of the EQ-5D scores suggested that the use of
classical parametric tests to compare the two sets of
scores may not be appropriate. Therefore, the Wilcoxon
signed-rank test was used to test the difference in medians
and distributions. The Spearman rank correlation coefﬁ-
cient was used to measure the association and a Bland-
Altman plot to describe the agreement between the sets at
6 months. The discriminatory power of the instruments
was explored by comparing the proportion of patients
obtaining the ceiling score of 1 (ceiling effect). To ana-
lyse the agreement in the direction of change of the
HRQoL scores between 6 and 12 months, a 3 9 3 matrix
was constructed. The changes were classiﬁed according to
MID as negative, if the change was B-0.08 and B-0.03,
and positive, if the change was C0.08 and C0.03 for the
EQ-5D and 15D, respectively. Other values were classi-
ﬁed as unchanged. The McNemar-Bowker test was used
to test whether the instruments give a similar picture of
the changes (the matrix is symmetric) and Cohen’s kappa
to test the agreement between the instruments. The
p values\0.05 were considered statistically signiﬁcant.
Results
Both the 6- and 12-month questionnaires were returned by
998 patients (38% of the 2,600 patients alive). However,
69 of the EQ-5D questionnaires were not ﬁlled in com-
pletely, leaving 929 patients for ﬁnal analysis. Of them,
31% had been treated in an ICU and 69% in a HDU. For
characteristics of the study population, see electronic
material.
The distributions of the EQ-5D and 15D scores at
6 months are presented in Fig. 1. The distribution of the
2091EQ-5D scores was wide, three-peaked and discontinuous,
whereas that of the 15D was one-peaked and continuous.
The rank correlation between the two sets of scores was
0.811(p\0.001).Themean(median)utilitiesat6 months
were 0.832 (0.859) and 0.731 (0.760) for the 15D and EQ-
5D, respectively. The medians and distributions were dif-
ferent(p\0.001)andtheagreementbetweenthesetspoor
(Bland-Altman plot in electronic material). The EQ-5D
detected fewer health states than the 15D (at 6 months 79
vs. 767, at 12 months 70 vs. 745). Using the EQ-5D, 26%
of patients had a ceiling score of 1 compared to 6% for the
15D. Regarding the clinically important change in the
HRQoL scores between 6 and 12 months, the instruments
had the same direction of change in 53% of the patients.
The EQ-5D showed no change in 61% of patients, the 15D
in 46%. Overall, the instruments gave a different picture of
the changes (Bowker 53.9, p\0.001), and the agreement
between them was only fair (kappa 0.24, 95% CI 0.19,
0.29; (Table 1).
Discussion
Patient-reported outcomes such as HRQoL have gained
increased importance as measures of effectiveness of
health care. Of the HRQoL instruments used in the
assessment of critical care, only a few produce a utility
score necessary for the calculation of QALYs. These
include the EQ-5D and 15D, which we compared in this
large cohort study. Regardless of the statistical test used,
theagreementbetweentheinstrumentswasonlymoderate.
The main reason for this may be the wide, three-
peaked and discontinuous distribution of the TTO-based
EQ-5D scores with a high ceiling effect. Because of these
features of the EQ-5D scores, classical methodology used
for comparisons and evaluation of agreement between
scores may not be applicable. The existence of negative
utilities implies that HRQoL could be improved by dying,
which is not logically congruent with the objectives of
care, although from an ethical and economic point of
view, a permanent non-independent health state may be
worse than death. The distribution of the 15D scores (all
positive values) was one-peaked and continuous and,
importantly, only 6% of the patients evaluated their health
state as perfect at 6 months after critical illness, indicating
better discriminatory power of the 15D in minor health
problems. The EQ-5D detected fewer health states and
clinically important changes in HRQoL than the 15D. In
this light, the 15D appeared more sensitive than the EQ-
5D in terms of discriminatory power and responsiveness
to clinically important change, although in the absence of
a gold standard, it is not possible to say which instrument
is ‘‘right.’’ In these respects our results agree with those
obtained previously in a number of populations and
patient groups [13–15].
Strengths and limitations
One strength is that HRQoL was measured simulta-
neously by both instruments. Our comparison revealed,
therefore, differences and agreement regarding the
instruments. In addition, the patient population was large
(despite of the response rate of 38%). In general, the lack
of baseline HRQoL scores may be seen as a limitation,
Fig. 1 The distributions of the EQ-5D and 15D scores at 6 months
Table 1 The direction of the minimal clinically important change (MID) in the HRQoL scores between 6 and 12 months
Change greater than the MID (0.08) in the EQ-5D score Total
Negative (%) Unchanged (%) Positive (%)
Change greater than the MID (0.03)
in the 15D score
Negative (%) 10.1 11.8 2.8 24.7
Unchanged (%) 6.4 32.4 7.2 46.0
Positive (%) 1.6 16.8 10.9 29.3
Total (%) 18.1 61.0 20.9 100.0
2092but in the comparison of two instruments, as in our study,
does not pose a problem. ICU and HDU patients were
analysed together, but as only 34% of the sample belon-
ged to the ICU subset, our results do not necessarily
reveal how the instruments may work in comparison
when applied exclusively to ICU patients.
Conclusion
In conclusion, the 15D may be more sensitive than the
EQ-5D in terms of discriminatory power and respon-
siveness to clinically important change. The agreement
between the EQ-5D and 15D utilities was only moderate.
As utilities differ depending on the HRQoL instrument
used, the results of the cost-utility studies in the critically
ill are difﬁcult to compare. In the future, large cohort
studies are warranted to produce sufﬁcient comparative
evidence regarding utility measures, including the SF-6D
and the 15D, before the gold standard for utility mea-
surement may be announced.
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